12:00 AM
 | 
Mar 11, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Dolutegravir: Phase III data

The double-blind, double-dummy, international Phase III SAILING (ING111762) trial in 715 HIV-1 infected, antiretroviral therapy (ART)-experienced, integrase inhibitor-naïve patients showed that once-daily 50 mg dolutegravir met the secondary endpoint of non-inferiority to twice-daily 400 mg Isentress raltegravir in the proportion of patients with undetectable HIV-1 RNA levels (<50 copies/mL) at week 24 (79% vs. 70%, 95% CI for the difference: 3.4%, 15.9%). ViiV said that the difference between treatment groups on the endpoint was also statistically significant (p=0.003). At week 24, 15% of patients receiving dolutegravir had a virologic non-response vs. 24% of patients...

Read the full 460 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >